Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
CNOOC
00883
5
SINOPEC CORP
00386
| (Q1)Mar 31, 2026 | (FY)Dec 31, 2025 | (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 16.05%2.04B | 14.11%7.72B | 7.16%5.37B | 4.33%3.51B | 14.19%1.75B | 1.13%6.76B | -0.72%5.01B | -2.00%3.36B | -6.93%1.54B | -6.66%6.69B |
| Operating income | 16.05%2.04B | 14.11%7.72B | 7.16%5.37B | 4.33%3.51B | 14.19%1.75B | 1.13%6.76B | -0.72%5.01B | -2.00%3.36B | -6.93%1.54B | -6.66%6.69B |
| Cost of sales | ---- | -1.21%-6.08B | ---- | 4.50%-2.93B | ---- | -7.09%-6.01B | ---- | -6.21%-3.07B | ---- | 6.55%-5.61B |
| Operating expenses | -7.61%-1.59B | -1.21%-6.08B | 4.11%-4.33B | 4.50%-2.93B | -7.01%-1.48B | -7.09%-6.01B | -7.09%-4.51B | -6.21%-3.07B | 1.22%-1.38B | 6.55%-5.61B |
| Gross profit | 61.39%444.44M | 117.14%1.63B | 108.19%1.05B | 97.39%574.8M | 78.56%275.39M | -29.98%752.61M | -39.97%502.9M | -46.00%291.2M | -38.68%154.22M | -7.26%1.07B |
| Selling expenses | 14.15%-15.18M | -21.63%-71.28M | -23.02%-40.86M | -8.66%-27.84M | -67.00%-17.68M | -67.06%-58.61M | -56.44%-33.22M | -143.00%-25.62M | -3.90%-10.59M | 2.84%-35.08M |
| Administrative expenses | -43.64%-70.41M | -61.37%-312.83M | -34.22%-157.15M | -18.33%-94.44M | -20.95%-49.02M | -5.20%-193.86M | -26.38%-117.09M | -11.36%-79.81M | -77.87%-40.53M | -6.84%-184.27M |
| Research and development expenses | -47.70%-122.24M | -57.60%-505.69M | -37.31%-315.88M | -11.12%-169.83M | -10.96%-82.76M | 9.33%-320.88M | 10.29%-230.04M | 12.54%-152.84M | -3.84%-74.59M | -4.86%-353.88M |
| Profit from asset sales | -2,774.05%-1.26M | ---- | 296.77%371.24K | ---- | -81.62%47.22K | ---- | 39.48%-188.66K | ---- | 590.90%256.97K | ---- |
| Revaluation surplus | --202.3K | ---- | 74.75%-614K | ---- | ---- | ---- | -123.29%-2.43M | ---- | ---- | ---- |
| -Changes in the fair value of other assets | --202.3K | ---- | 74.75%-614K | ---- | ---- | ---- | -123.29%-2.43M | ---- | ---- | ---- |
| Impairment and provision | -13.51%-15.02M | -63.77%-71.94M | -54.54%-54.86M | -72.86%-38.45M | 10.73%-13.24M | -83.98%-43.93M | -70.63%-35.5M | -78.64%-22.25M | -136.93%-14.83M | -7.48%-23.88M |
| -Impairment of property, machinery and equipment | ---- | ---11.52M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| -Goodwill impairment | ---- | ---- | ---- | ---- | ---- | ---3.38M | ---- | ---- | ---- | ---- |
| -Other impairment is provision | -13.51%-15.02M | -49.01%-60.42M | -54.54%-54.86M | -72.86%-38.45M | 10.73%-13.24M | -69.81%-40.55M | -70.63%-35.5M | -78.64%-22.25M | -136.93%-14.83M | -7.48%-23.88M |
| Special items of operating profit | -64.85%22.74M | -8.83%195.47M | -18.98%106.6M | -16.76%118.19M | -28.46%64.68M | 36.39%214.41M | 134.11%131.58M | 55.41%141.98M | 45.22%90.42M | 150.23%157.2M |
| Operating profit | 35.24%232.37M | 148.17%867.98M | 185.50%559.76M | 137.39%362.42M | 71.74%171.82M | -44.92%349.75M | -60.39%196.07M | -57.73%152.67M | -49.57%100.05M | -2.84%635.01M |
| Financing income | -36.35%13.95M | ---- | 11.88%47.07M | ---- | 28.42%21.92M | ---- | 205.47%42.07M | ---- | 225.66%17.07M | ---- |
| Financing cost | -260.88%-28.16M | -75.17%-81.88M | -75.55%-46.25M | 1.69%-25.68M | -20.43%-7.8M | 9.20%-46.75M | 33.60%-26.34M | 6.43%-26.12M | 51.47%-6.48M | 25.26%-51.48M |
| Share of profits of associates | ---- | -91.55%156K | ---- | -28.54%358K | ---- | 378.24%1.85M | ---- | 183.05%501K | ---- | 129.97%386K |
| Special items of earning before tax | -9,107.95%-1.7M | -69.91%3.03M | 70.14%-500.96K | 3,471.98%12.27M | 147.36%18.88K | -69.50%10.08M | 2.05%-1.68M | -101.29%-364K | 100.86%7.63K | -81.97%33.04M |
| Earning before tax | 12.55%207.36M | 150.63%789.29M | 161.28%571.25M | 175.79%349.37M | 60.68%184.24M | -48.95%314.93M | -59.16%218.64M | -64.97%126.68M | -39.67%114.66M | -19.53%616.96M |
| Tax | ---- | -200.26%-62.39M | ---- | -572.69%-39.92M | ---- | 58.51%-20.78M | ---- | 78.52%-5.94M | ---- | 19.38%-50.08M |
| After-tax profit from continuing operations | 17.94%191.67M | 147.12%726.9M | 161.39%524.28M | 156.28%309.45M | 59.03%162.51M | -48.11%294.15M | -59.64%200.57M | -63.85%120.75M | -42.86%102.19M | -19.54%566.88M |
| Earning after tax | 17.94%191.67M | 147.12%726.9M | 161.39%524.28M | 156.28%309.45M | 59.03%162.51M | -48.11%294.15M | -59.64%200.57M | -63.85%120.75M | -42.86%102.19M | -19.54%566.88M |
| Minority profit | -155.77%-1.11M | 585.70%21.29M | 139.22%8.82M | 320.79%4.49M | 297.01%1.99M | -2.54%3.11M | 35.57%3.69M | -23.28%1.07M | -20.56%500.76K | 67.86%3.19M |
| Profit attributable to shareholders | 20.09%192.77M | 142.44%705.61M | 161.81%515.46M | 154.81%304.95M | 57.85%160.53M | -48.37%291.04M | -60.17%196.88M | -64.02%119.68M | -42.93%101.69M | -19.78%563.69M |
| Basic earnings per share | 16.67%0.14 | 136.36%0.52 | 153.33%0.38 | 144.44%0.22 | 50.00%0.12 | -47.62%0.22 | -59.46%0.15 | -64.00%0.09 | -38.46%0.08 | -20.75%0.42 |
| Diluted earnings per share | 16.67%0.14 | 136.36%0.52 | 153.33%0.38 | 144.44%0.22 | 50.00%0.12 | -47.62%0.22 | -59.46%0.15 | -64.00%0.09 | -38.46%0.08 | -19.23%0.42 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS |
| Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion |
| Auditor | -- | Ernst & Young Huaming Certified Public Accountants (Special General Partnership) | -- | -- | -- | Ernst & Young Huaming Certified Public Accountants (Special General Partnership) | -- | -- | -- | Ernst & Young Huaming Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.